December 15, 2011
Chugai Pharmaceutical and Taisho Pharmaceutical announced on December 14 that ibandronate sodium hydrate injection, a bisphosphonate the two companies are jointly developing, had demonstrated non-inferiority in efficacy of reducing the incidence of new vertebral fractures compared to sodium risedronate hydrate...read more